Share article

Breakthrough in Tissue Cryopreservation for Organoid Generation

Can organoid success start with cryopreservation?
Discover how Pentahibe Complete enabled 100% organoid establishment from preserved biopsies, in collaboration with the Cambridge Stem Cell Institute.

June 2025 – Holbæk, Denmark

 

Pharmacosmos is proud to announce a significant milestone in disease modeling: Pentahibe Complete has demonstrated outstanding results in a new application—tissue cryopreservation for organoid generation.

 

This advance strengthens Pentahibe Complete’s position as a next-generation cryopreservation medium, now extending its robust benefits beyond cells to biopsy-based organoid research and biobanking.

 

Exceptional Results from the Zilbauer Group at Cambridge Stem Cell Institute

Preliminary research led by the Zilbauer Group at the Cambridge Stem Cell Institute has shown that Pentahibe Complete significantly outperforms conventional 10% DMSO-based media in preserving patient-derived intestinal biopsies.


Key findings include:

  • 100% organoid establishment success from duodenum, ileum, and colon samples

  • Increased organoid count and sustained growth post-thaw

  • Clear morphological integrity observed in time-lapse imaging up to day 13

These results indicate superior post-thaw tissue viability and structural preservation, confirming Pentahibe as a powerful tool for translational researchers and biobankers working with complex 3D models and patient tissues.

See more organoid generation data here under the organoid generation section.

“We see this as a major step toward enabling more reliable, reproducible organoid culture from biobanked tissues,”

- Tina Kristensen Marwood, International Carbohydrate & Cell Media Scientist

A Commitment to Collaboration

 

Pharmacosmos continues to advance innovation through strategic partnerships. Our work with the Zilbauer Group exemplifies how academic-industry collaboration can unlock new therapeutic and research pathways.

We actively welcome partnerships with biotech companies, academic institutions, and clinical labs to explore and adapt Pentahibe across diverse applications in tissue and cell preservation.

Enabling the Future of Cryopreservation

With its safe, low-DMSO (2%) formulation and proven compatibility with a wide range of cell types  – including T cells, MSCs, CHO and HEK cell lines, and now patient-derived tissue samples – PentaHibe Complete is advancing the next generation of cryopreservation.

From cancer immunotherapy and regenerative cell therapies to tissue banking and organoid development, PentaHibe empowers scientists with a high-performance solution.

 

Whether you are aiming to reduce DMSO concentration, expand organoid programs, or optimize your biobanking strategy, Pentahibe Complete delivers performance across demanding workflows.

🔗 Explore the PentaHibe Portfolio
📩 Contact us at pentahibe@pharmacosmos.com to discuss potential collaboration.

Evidence of Pentahibe performance
Pentahibe's organoid generation data

Explore PentaHibe Complete organoid generation data from the Cambridge Stem Cell Institute

Stay updated on PentaHibe and cryopreservation trends – subscribe to our newsletter
©2024 PHARMACOSMOS A/S This website contains information on products which is targeted to a wide range of audiences outside US and may contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. All rights reserved.
Helpful links
Navigation
Contact
  • Pharmacosmos A/S
  • Roervangsvej 30
  • DK-4300 Holbaek
  • Denmark
www.pharmacosmos.com